Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients

Jason D. Doles, Kelly A. Hogan, Jennifer O'Connor, Andrea E. Wahner Hendrickson, Olivia Huston, Aminah Jatoi

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients'. Together they form a unique fingerprint.

Medicine & Life Sciences